Compare Nuvalent Inc (NUVL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvalent Inc vs Novo Nordisk A/S — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while Novo Nordisk A/S trades at $49.32 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 22.5× Nuvalent Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| NUVL | NVO | |
|---|---|---|
Market Cap | $9.81B | $220.53B |
Sector | Technology | Health |
52-Week High | $123.96 | $71.70 |
52-Week Low | $72.16 | $35.29 |
Enterprise Value | $8.52B | $239.49B |
Dividend Yield | — | 3.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
